ER Productions Limited/Getty Images(NEW YORK) After decades of researching respiratory syncytial virus, an illness especially dangerous for newborns and the elderly, scientists this week announced a major development in plans for a possible vaccine that could be available as soon as next year. "Among very young children, particularly those [younger] than 6 months of age, we have a high probability now of protecting against serious illness and hospitalization," Pfizer's Dr. William Gruber told ABC News. Gruber is responsible for the company's vaccine development programs and has been personally working on the RSV vaccine for over 40 years. Pfizer announced Tuesday that given promising preliminary data on their maternal RSV vaccine for newborns, the Food and Drug Administration granted a green light to stop enrolling new patients in the study. The company said it will move forward with the vaccine approval process. Pfizer's traditional protein-based RSV vaccine
After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year
localnews8.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from localnews8.com Daily Mail and Mail on Sunday newspapers.
After promising trial results for maternal RSV vaccine, Pfizer says it will seek FDA approval this year
local3news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from local3news.com Daily Mail and Mail on Sunday newspapers.
Pfizer announces promising developments for 1st maternal RSV vaccine
abccolumbia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from abccolumbia.com Daily Mail and Mail on Sunday newspapers.